Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
At the present time evidential base on bosentan use comprises more randomized control trials results compared with other Lag-specific medications. Bosentan can be successfully used as monotherapy of in combination with medications of other groups in patients with idiopathic pulmonary hypertension (P...
Main Authors: | O A Arkhipova, T V Martynyuk |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Morozov P.V.
2018-06-01
|
Series: | Системные гипертензии |
Subjects: | |
Online Access: | https://syst-hypertension.ru/2075-082X/article/viewFile/29610/pdf |
Similar Items
-
Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: Arkhipova O.A., et al.
Published: (2018-05-01) -
Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan
by: S N Avdeev
Published: (2015-09-01) -
Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension
by: N A Tsareva
Published: (2013-12-01) -
Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
by: Z S Valieva, et al.
Published: (2017-08-01) -
First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study
by: S N Avdeev, et al.
Published: (2013-03-01)